Rituximab in Myasthenia Gravis: a real-world study using inverse probability of treatment weighting - Takeaways - MDSpire

Rituximab in Myasthenia Gravis: a real-world study using inverse probability of treatment weighting

  • By

  • Yong Lin Wang

  • Chao Zhu

  • Mahima Kapoor

  • Gary Cutter

  • Carolina Barnett-Tapia

  • Helmut Butzkueven

  • Wenwen Zhang

  • Gabor Lovas

  • Csilla Rozsa

  • Jeannine Heckmann

  • Stefan Blum

  • Laurie McLaughlin

  • Katherine Buzzard

  • Yi Chao Foong

  • Elisabeth Chroni

  • Dimitra Veltsista

  • Belinda Cruse

  • Mina Botrous

  • Stephen Reddel

  • Mastura Monif

  • Anneke van der Walt

  • July 2, 2026

  • 0 min

Share

  • 1

    Rituximab's effectiveness in treating myasthenia gravis (MG) remains uncertain due to limited randomized controlled evidence.

  • 2

    The study evaluated rituximab's effectiveness against a second non-steroidal immunosuppressive therapy (NSIST) in AChR-Ab positive MG patients.

  • 3

    A total of 169 patients were analyzed, with baseline characteristics balanced after inverse probability of treatment weighting (IPTW) adjustment.

  • 4

    The hazard ratio for rituximab compared to a second NSIST in achieving a composite clinical outcome was 1.27, indicating no statistical difference.

  • 5

    The analysis concluded that rituximab did not improve time-to-improvement compared to a second NSIST in AChR-Ab-positive MG patients.

Original Source(s)

Rituximab in Myasthenia Gravis: a real-world study using inverse probability of treatment weighting

  • by Yong Lin Wang, Chao Zhu, Mahima Kapoor, Gary Cutter, Carolina Barnett-Tapia, Helmut Butzkueven, Wenwen Zhang, Gabor Lovas, Csilla Rozsa, Jeannine Heckmann, Stefan Blum, Laurie McLaughlin, Katherine Buzzard, Yi Chao Foong, Elisabeth Chroni, Dimitra Veltsista, Belinda Cruse, Mina Botrous, Stephen Reddel, Mastura Monif, Anneke van der Walt

  • July 2, 2026

Related Content

Urbanicity, Neighborhood Conditions, and Dementia Mortality

Diffusion tensor imaging in chronic tension-type headache

Diabetes-duration-related shifts in inflammation-resolving lipid mediator signatures and their association with 3-month functional outcome in large artery atherosclerotic stroke